Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00870103 · ClinicalTrials.gov registry record · Phase 4
Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery
A Phase 4 study of Cataract, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT00870103 is a Phase 4 study of Cataract that has completed, run by Alcon Research. The registered enrollment target is 64 participants, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00870103, a Phase 4 study of Cataract, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
To demonstrate that the combination formulation of Moxifloxacin/Dexamethasone Eye Drop is effective and safe for the prevention of postoperative inflammation as a consequence of cataract extraction surgery.
Conditions Studied
Interventions
- DRUG Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
Study Locations (1)
Texas
- Alcon Call Center - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2008-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00870103
The ClinicalTrials.gov registry entry for NCT00870103 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (72% lower). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 1 intervention - of which Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops is the first listed.
NCT00870103 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00870103 about?
NCT00870103 is a clinical study titled "Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery". To demonstrate that the combination formulation of Moxifloxacin/Dexamethasone Eye Drop is effective and safe for the prevention of postoperative inflammation as a consequence of cataract extraction surgery.
What is the current status of trial NCT00870103?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 64 participants. The study started on 2008-09.
What conditions does trial NCT00870103 study?
This clinical trial studies the following conditions: Cataract.
What interventions are being tested in trial NCT00870103?
The interventions under investigation include: Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops (DRUG).
Who is sponsoring clinical trial NCT00870103?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00870103 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataract
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population
RECRUITING · Phase 4
-
A Prospective, Randomized, Subject and Vision-assessor Masked, Multicenter Study Comparing Bilateral Clareon PanOptix, Bilateral Clareon PanOptix Pro, and Mixed Clareon PanOptix Pro/Vivity Intraocular Lens Implantation in Cataract Subjects
RECRUITING · Phase 4
-
Evaluation of a Monofocal Intraocular Lens
RECRUITING · Phase 4
-
Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
RECRUITING · Phase 4
-
Odyssey Evaluation in Post LASIK Patients
RECRUITING · Phase 4
-
Dropless vs. Standard Drops Contralateral Eye Study
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.